187 related articles for article (PubMed ID: 37528249)
1. Increased serum soluble interleukin-2 receptor levels in dermatomyositis are associated with Th17/Treg immune imbalance.
Xie Y; Zhang T; Su R; Liu L; Jiang L; Xue H; Gao C; Li X; Wang C
Clin Exp Med; 2023 Nov; 23(7):3605-3617. PubMed ID: 37528249
[TBL] [Abstract][Full Text] [Related]
2. Soluble IL-2 Receptor in Dermatomyositis: Its Associations with Skin Ulcers and Disease Activity.
He L; Shu X; Liu X; Ge Y; Li S; Lu X; Wang G
Mediators Inflamm; 2020; 2020():6243019. PubMed ID: 32774147
[TBL] [Abstract][Full Text] [Related]
3. Low-dose IL-2 therapy restores imbalance between Th17 and regulatory T cells in patients with the dermatomyositis combined with EBV/CMV viremia.
Zheng X; Su R; Hu F; Liu Y; Li X; Gao C; Wang C
Autoimmun Rev; 2022 Nov; 21(11):103186. PubMed ID: 36084894
[TBL] [Abstract][Full Text] [Related]
4. Absolute reduction of regulatory T cells and regulatory effect of short-term and low-dose IL-2 in polymyositis or dermatomyositis.
Feng M; Guo H; Zhang C; Wang Y; Liang Z; Zhao X; Qin Y; Wu Y; Liu G; Gao C; Luo J
Int Immunopharmacol; 2019 Dec; 77():105912. PubMed ID: 31669890
[TBL] [Abstract][Full Text] [Related]
5. Decreased absolute number of peripheral regulatory T cells in patients with idiopathic retroperitoneal fibrosis.
Liu L; Yan H; Wang Y; Xie Y; Jiang L; Zhao J; Gao C; Li X; Wang C
Front Immunol; 2022; 13():1012513. PubMed ID: 36524110
[TBL] [Abstract][Full Text] [Related]
6. Elevated serum IL-2 and Th17/Treg imbalance are associated with gout.
Zi X; Su R; Su R; Wang H; Li B; Gao C; Li X; Wang C
Clin Exp Med; 2024 Jan; 24(1):9. PubMed ID: 38240927
[TBL] [Abstract][Full Text] [Related]
7. Elevated serum levels of neopterin in adult patients with polymyositis/dermatomyositis.
Samsonov MY; Nassonov EL; Tilz GP; Geht BM; Demel U; Gurkina GT; Shtutman VZ; Guseva AG; Wachter H; Fuchs D
Br J Rheumatol; 1997 Jun; 36(6):656-60. PubMed ID: 9236675
[TBL] [Abstract][Full Text] [Related]
8. Serum cytokines in juvenile rheumatoid arthritis. Correlation with conventional inflammation parameters and clinical subtypes.
Mangge H; Kenzian H; Gallistl S; Neuwirth G; Liebmann P; Kaulfersch W; Beaufort F; Muntean W; Schauenstein K
Arthritis Rheum; 1995 Feb; 38(2):211-20. PubMed ID: 7848311
[TBL] [Abstract][Full Text] [Related]
9. Preliminary Study on the Imbalance Between Th17 and Regulatory T Cells in Antiphospholipid Syndrome.
Yan H; Li B; Su R; Gao C; Li X; Wang C
Front Immunol; 2022; 13():873644. PubMed ID: 35603166
[TBL] [Abstract][Full Text] [Related]
10. Serum concentration of interleukin 15, interleukin 2 receptor and TNF receptor in patients with polymyositis and dermatomyositis: correlation to disease activity.
Mielnik P; Chwalinska-Sadowska H; Wiesik-Szewczyk E; Maslinski W; Olesinska M
Rheumatol Int; 2012 Mar; 32(3):639-43. PubMed ID: 21132303
[TBL] [Abstract][Full Text] [Related]
11. Relationship between the absolute lymphocyte count/absolute monocyte count ratio, soluble interleukin 2 receptor level, serum programmed cell death 1 level, and the prognosis of patients with diffuse large B-cell lymphoma.
Li C; Li W; Xu G; You M; Wu W; Kuang L
Ann Palliat Med; 2021 Oct; 10(10):10938-10945. PubMed ID: 34763456
[TBL] [Abstract][Full Text] [Related]
12. Elevated circulating soluble interleukin-2 receptor in patients with chronic liver diseases is associated with non-classical monocytes.
Seidler S; Zimmermann HW; Weiskirchen R; Trautwein C; Tacke F
BMC Gastroenterol; 2012 Apr; 12():38. PubMed ID: 22530792
[TBL] [Abstract][Full Text] [Related]
13. Soluble IL-2 receptor: a biomarker for assessing myositis activity.
Tournadre A; Dubost JJ; Soubrier M; Ruivard M; Souteyrand P; Schmidt J; Clavelou P; Tridon A; Ristori JM
Dis Markers; 2014; 2014():472624. PubMed ID: 24648607
[TBL] [Abstract][Full Text] [Related]
14. Soluble interleukin-2 receptor in sera and synovial fluids of rheumatoid patients: correlations with disease activity.
Carotti M; Salaffi F; Ferraccioli GF; Binci MC; Sartini A; Cervini C
Rheumatol Int; 1994; 14(2):47-52. PubMed ID: 7824835
[TBL] [Abstract][Full Text] [Related]
15. Serum soluble IL-2 receptor as a marker of lymphocyte activation in some autoimmune diseases. Effect of immunosuppressive therapy.
Dejica D
Roum Arch Microbiol Immunol; 2001; 60(3):183-201. PubMed ID: 12165973
[TBL] [Abstract][Full Text] [Related]
16. Frequency of HLA-DR
Nguyen TH; Kumar D; Prince C; Martini D; Grunwell JR; Lawrence T; Whitely T; Chappelle K; Chonat S; Prahalad S; Briones M; Chandrakasan S
J Allergy Clin Immunol; 2024 Jan; 153(1):309-319. PubMed ID: 37517575
[TBL] [Abstract][Full Text] [Related]
17. The role of interleukin 2 (IL-2) and serum-soluble IL-2 receptor cells in idiopathic IgA nephropathy.
Parera M; Rivera F; Egido J; Campos A
Clin Immunol Immunopathol; 1992 May; 63(2):196-9. PubMed ID: 1351798
[TBL] [Abstract][Full Text] [Related]
18. Soluble interleukin-2 receptors in sera of children with primary malignant neoplasms.
Bodey B; Psenko V; Lipsey AL; Kaiser HE
Anticancer Res; 1996; 16(1):219-24. PubMed ID: 8615612
[TBL] [Abstract][Full Text] [Related]
19. Elevated serum levels of soluble interleukin-2 receptor: a marker of disease activity in the hypereosinophilic syndrome.
Prin L; Plumas J; Gruart V; Loiseau S; Aldebert D; Ameisen JC; Vermersch A; Fenaux P; Bletry O; Capron M
Blood; 1991 Nov; 78(10):2626-32. PubMed ID: 1726707
[TBL] [Abstract][Full Text] [Related]
20. The significance of an increase in soluble interleukin-2 receptor level in colorectal cancer and its biological regulating role in the physiological switching of the immune response cytokine network from TH1 to TH2 and back.
Berghella AM; Pellegrini P; Del Beato T; Marini M; Tomei E; Adorno D; Casciani CU
Cancer Immunol Immunother; 1998 Jan; 45(5):241-9. PubMed ID: 9439647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
